Amphastar Pharma (AMPH) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2019
November 7, 2019 4:06 PM ESTReports Net Revenues of $80.1 Million for the Three Months Ended September 30, 2019
RANCHO CUCAMONGA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended September 30, 2019.
Third Quarter Highlights
Net revenues of $80.1 million for the third quarterGAAP net income of $1.3 million, or $0.03 per share, for the third quarterAdjusted non-GAAP net income of $5.2 million, or $0.10 per share, for the third quarterDr. Jack Zhang, Amphastars Chief Executive Officer, commented: A significant accomplishment... More
